Improving Shingrix Vaccination Among US Veterans Receiving Immunosuppression

NCT06596148 | Enrolling By Invitation

• 2 other identifiers: 15-18358- SHINGRIXI50HX003266
• Study Type: interventional
• Target: 130
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this wait-list control trial is to learn if having access to a new dashboard displaying information about immunosuppressed Veterans missing vaccinations for Shingrix can improve Shingrix vaccination rates at VA facilities. The main question\[s\] it aims to answer is: Will vaccination rates improve more rapidly for facilities with access to the dashboard compare to facilities without access? VA facility personnel will be granted access to the dashboard and outcomes (vaccination rates) will be measured using electronic health record data.

Conditions

Immunosuppresion

Keywords

Wait-list control randomized trial

Outcome Measures

Primary Outcomes (1)

• Percentage of patients with at least 1 Shingrix vaccine documented, by facility

  Percentage of patients with at least 1 Shingrix vaccinations documented, by facility

  From enrollment until end of follow up at 18 months.

Secondary Outcomes (1)

• Percentage of patients with at least 2 Shingrix vaccinations documented, by facility

  From enrollment until end of follow up at 18 months.

Study Arms (2)

Early dashboard access

EXPERIMENTAL

The early dashboard access arm will receive access to the Shingrix dashboard as soon as the study begins.

Other: Access to Shingrix dashboard

Wait list control arm

OTHER

The wait list control arm will receive no intervention for 6-9 months; after this period, this arm will also receive access to the Shingrix dashboard.

Other: Access to Shingrix dashboard

Interventions

Access to Shingrix dashboard OTHER

The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic health record permissions.

Early dashboard access; Wait list control arm

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• In order to be included in the study, clinicians need to work at a VHA facility and have access to the electronic health record.

You may not qualify if:

• None.

Sponsors & Collaborators

• University of California, San Francisco: lead
• San Francisco Veterans Affairs Medical Center: collaborator

Study Sites (1)

San Francisco VA

San Francisco, California, 94121, United States

Location

Study Officials

• Gabriela Schmajuk, MD MS

  San Francisco VA Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: The investigators will use a wait-list control design; clinicians from VA facilities will be randomized to receive access to the dashboard early vs. after a 6-9 month delay. The investigators will compare Shingrix vaccination rates in the two groups of facilities.

Study Record Dates

• First Submitted: September 9, 2024
• First Posted: September 19, 2024
• Study Start: September 16, 2024
• Primary Completion: March 1, 2026
• Study Completion (Estimated): June 30, 2026
• Last Updated: April 6, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)